Zobrazeno 1 - 10
of 176
pro vyhledávání: '"Jonathan E. Kolitz"'
Autor:
Robert K. Stuart, Grerk Sutamtewagul, Ann-Kathrin Eisfeld, Ravi Vij, Krzysztof Mrózek, Jessica Kohlschmidt, Mohan Thakuri, Richard Stone, William Blum, Wendy Stock, Andrew J. Carroll, Jonathan E. Kolitz, Richard A. Larson, Guido Marcucci, Eunice S. Wang, Clara D. Bloomfield, Jun Yin, John C. Byrd, Alison Walker, Sawyer B. Jacobson
Publikováno v:
Blood Adv
Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with unfavorable outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide dire
Autor:
Dale L. Bixby, Jeffrey E. Lancet, Robert K. Stuart, Scott R. Solomon, Laura F. Newell, Ellen K. Ritchie, Donna E. Hogge, Geoffrey L. Uy, Daniel H. Ryan, Stephen A. Strickland, Gary J. Schiller, Stefan Faderl, Tara L. Lin, Jorge E. Cortes, Jonathan E. Kolitz, Matthew J Wieduwilt
Publikováno v:
The Lancet Haematology. 8:e481-e491
Summary Background Daunorubicin and cytarabine are used as standard induction chemotherapy for patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. Prim
Autor:
James S. Blachly, Uma Borate, Eunice S. Wang, Bhavana Bhatnagar, Ross L. Levine, Ann-Kathrin Eisfeld, Amy Burd, John C. Byrd, Richard Stone, Brian J. Druker, Alice S. Mims, Krzysztof Mrόzek, Eytan M. Stein, Bayard L. Powell, Jonathan E. Kolitz, Clara D. Bloomfield, Shelley Orwick, Jessica Kohlschmidt, Dimitrios Papaioannou, Deedra Nicolet
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-15 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Older patients (≥ 60 years) with acute myeloid leukemia (AML) often have multiple, sequentially acquired, somatic mutations that drive leukemogenesis and are associated with poor outcome. Beat AML is a Leukemia and Lymphoma Society-spons
Autor:
Donna E. Hogge, Jonathan E. Kolitz, Stefan Faderl, Daniel H. Ryan, Tara L. Lin, Jeffrey E. Lancet, Matthew J. Wieduwilt, Robert J. Ryan, Scott R. Solomon, Jorge E. Cortes, Geoffrey L. Uy, David A. Rizzieri, Gary J. Schiller
Publikováno v:
Blood Adv
CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine in a synergistic 1:5 molar ratio, is approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related
Autor:
Jessica Kohlschmidt, Richard Stone, Dimitrios Papaioannou, Clara D. Bloomfield, Adrienne M. Dorrance, Marius Bill, Bayard L. Powell, Andrew J. Carroll, Deedra Nicolet, Jonathan E. Kolitz, Ramiro Garzon, John C. Byrd, Ann-Kathrin Eisfeld, Zachary Brannan, Xiaoqing Rong-Mullins, Krzysztof Mrózek, Kellie J. Archer, Christopher J. Walker
Publikováno v:
Haematologica
Leukemia stem cells (LSC) are more resistant to standard chemotherapy and their persistence during remission can cause relapse, which is still one of the major clinical challenges in the treatment of acute myeloid leukemia (AML). A better understandi
Autor:
Sophia E. Maharry, Clara D. Bloomfield, Marius Bill, Sandya Liyanarachchi, Christopher C. Oakes, Chi Song, Christopher J. Walker, Albert de la Chapelle, Geoffrey L. Uy, Brian Giacopelli, James S. Blachly, Bayard L. Powell, Eunice S. Wang, Shelley Orwick, Jonathan E. Kolitz, Richard Stone, Deedra Nicolet, Kellie J. Archer, Ann-Kathrin Eisfeld, John C. Byrd, Luke K Genutis, Jessica Kohlschmidt, Dimitrios Papaioannou, Krzysztof Mrózek, Andrew J. Carroll
Publikováno v:
Clin Cancer Res
Purpose:Uniparental disomy (UPD) is a way cancer cells duplicate a mutated gene, causing loss of heterozygosity (LOH). Patients with cytogenetically normal acute myeloid leukemia (CN-AML) do not have microscopically detectable chromosome abnormalitie
Autor:
James S. Blachly, Andrew J. Carroll, John C. Byrd, Christopher C. Oakes, Sydney Fobare, Shelley Orwick, Richard Stone, Krzysztof Mrózek, Alice S. Mims, Eunice S. Wang, Hatice Gulcin Ozer, Bayard L. Powell, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Ramiro Garzon, Jessica Kohlschmidt, Deedra Nicolet, Erin Hertlein
Publikováno v:
Blood advances. 6(5)
Prognostic factors associated with chemotherapy outcomes in patients with acute myeloid leukemia (AML) are extensively reported, and one gene whose mutation is recognized as conferring resistance to several newer targeted therapies is protein tyrosin
Autor:
Marius Bill, Bayard L. Powell, John C. Byrd, Brian Giacopelli, Jessica Kohlschmidt, Jonathan E. Kolitz, Dimitrios Papaioannou, Christopher C. Oakes, Ramiro Garzon, Krzysztof Mrózek, Richard Stone, Andrew J. Carroll, Ann-Kathrin Eisfeld, Deedra Nicolet, Clara D. Bloomfield
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Recently, a novel knowledge bank (KB) approach to predict outcomes of individual patients with acute myeloid leukemia (AML) was developed using unbiased machine learning. To validate its prognostic value, we analyzed 1612 adults with de novo AML trea
Autor:
Jonathan E. Kolitz, Susan M. Christner, Michaela Liedtke, Richard Stone, Geoffrey L. Uy, Meir Wetzler, Jan H. Beumer, Lionel D. Lewis, Jun Yin, Matthew J Wieduwilt, Wendy Stock, Elizabeth Storrick, Richard A. Larson, Steven M. Devine, Ryan J. Mattison, Bayard L. Powell
Publikováno v:
Blood Advances
Key Points Dasatinib and dexamethasone induction then allogeneic hematopoietic cell transplantation was feasible and effective for untreated Ph+ ALL.Treatment failure was associated with BCR-ABL1 T315I mutation, the p210 BCR-ABL1 isoform, or isolated
Autor:
Jessica Kohlschmidt, Dimitrios Papaioannou, Clara D. Bloomfield, Paolo Fadda, Deedra Nicolet, Richard Stone, Andrew J. Carroll, John C. Byrd, Eunice S. Wang, Hatice Gulcin Ozer, Stefano Volinia, Jonathan E. Kolitz, Ramiro Garzon, Krzysztof Mrózek
Publikováno v:
Molecular Cancer Therapeutics. 18:1451-1459
We have previously shown that expression levels of 48 long noncoding RNAs (lncRNA) can generate a prognostic lncRNA score that independently associates with outcome of older patients with cytogenetically normal acute myeloid leukemia (CN-AML). Howeve